Dec 7 (Reuters) - Sierra Oncology Inc SRRA.O :
* SIERRA ONCOLOGY ANNOUNCES MOMELOTINIB DATA FOR INTERMEDIATE / HIGH-RISK MYELOFIBROSIS PATIENTS WITH LOWER BASELINE PLATELET COUNTS
* SIERRA ONCOLOGY - RETROSPECTIVE ANALYSES OF PHASE 3 SIMPLIFY STUDIES DEMONSTRATE SAFETY & ACTIVITY PROFILE ARE NOT IMPACTED BY BASELINE PLATELET COUNT